الفهرس 
Multiple mylomaOnly 14 pages are availabe for public view
 |  | from | 156 |  |  |
| | | from | 156 | | |
Abstract
Abstract: The discovery of new molecules and cancer pathophysiology
mechanisms is a research cornerstone for the open era of targeted
immunotherapy development. Multiple myeloma is one of the more easily
cured haematological malignancies in the era of targeted therapy, but there
is a gap of resistant or relapsed patients, and new pathways of cellular
division and proliferation could be possible with targeted therapy. Prohibtin
is one of those proteins that has been studied in different kinds of
malignancies and found to be overexpressed in malignancies; it has been
studied in myeloma, and clinical trials are going on for targeted therapy.
Methods: Prohibitin expression was measured in peripheral blood samples
from 50 myeloma patients before and after autologous bone marrow
transplantation using ELISA kits. Its association with different prognostic
and clinicopathological parameters was also evaluated.
Results: The median percentage of Prohibitin level in myeloma patients
before autologous HSCT was significantly higher than after, and it was
significantly associated with poor overall survival. Besides, overexpression
of Prohibitin was significantly higher in patients with partial remission than
complete remission (P< 0.001).
Conclusion: This study identifies Prohibitin as a poor prognostic marker in
patients with myeloma and highlights the myeloablative effect of HSCT
due to a low undesirable Prohibitin level